RNAC — Cartesian Therapeutics Share News
0.000.00%
Last trade - 00:00- $186.98m
- $92.22m
- $2.80m
Cartesian Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Cartesian Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Cartesian Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
Brief: Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial
Cartesian Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview
Brief: Cartesian Therapeutics Highlights Progress And 2025 Strategic Priorities
Cartesian Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview
Brief: Cartesian Therapeutics Reports Q3 2024 Financial Results And Provides Business Update
Brief: TAS Partners Llc Reports 2.4% Stake In Cartesian Therapeutics As Of Oct 2 Versus 11.7% As Of Sept 25 - SEC Filing
Brief: Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
U.S. RESEARCH ROUNDUP-Ardelyx, Eli Lilly, Tesla
Brief: Cartesian Therapeutics Announces $130 Mln Private Placement Equity Financing
Brief: Cartesian Therapeutics Announces First Patient Dosed In Phase 2 Trial Of Descartes-08 In Systematic Lupus Erythematosus
Brief: Cartesian Therapeutics Announces Positive Topline Results From Phase 2B Trial Of Descartes-08 In Patients With Myasthenia Gravis
Cartesian's immune disorder therapy meets main goal in mid-stage study (updated)
Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study
U.S. RESEARCH ROUNDUP-Honeywell International, Stericycle, Target Corp
U.S. STOCKS ON THE MOVE-Brady Corp, Moderna, crypto shares
U.S. STOCKS ON THE MOVE-Dorian, ChargePoint Holdings, Transcat